radium-223

Expanding the Role of Radium-223 (Xofigo)

One of the newer drugs and one that has recently had great air play is the bone targeting radiopharmaceutical drug radium-223 or Xofigo. Currently, it is approved for men with castrate resistant prostate cancer with bone metastases. The problem is that currently Xofigo is only approved for one round of treatment using 6 monthly infusions. [...]

By Malecare|2017-10-19T10:46:04-04:00October 18th, 2016|Advanced Prostate Cancer, Bone Metastases, Clinical Trials, Drugs & Treatments, radiopharmaceuticals, Uncategorized, Xofigo|0 Comments

Chemotherapy After Radium-223 Appears to be Safe in Men with Metastatic Castration-Resistant Prostate Cancer

Understanding how to best sequence and combine our new drugs to treat advanced prostate cancer includes the most discussed issue, efficacy. We want to know if a special order or a special combination of the approved drugs will nake a difference in both our quality of life (QoL) as well as how survival. Often [...]

By Malecare|2015-09-30T10:21:06-04:00September 30th, 2015|Advanced Prostate Cancer, Chemotherapy, Combination Therapy, Drugs & Treatments,